Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report released on Thursday morning,RTT News reports. The brokerage currently has a $31.00 price objective on the stock.

A number of other research firms have also recently weighed in on BCAX. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright raised their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Price Performance

Shares of BCAX stock opened at $13.40 on Thursday. The company has a 50 day moving average of $13.01. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, April 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). On average, analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of institutional investors have recently made changes to their positions in BCAX. California State Teachers Retirement System bought a new stake in Bicara Therapeutics during the fourth quarter worth approximately $25,000. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics during the 4th quarter valued at $31,000. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at $33,000. Finally, Summit Investment Advisors Inc. bought a new position in Bicara Therapeutics during the fourth quarter valued at about $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.